Stockreport

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1ß and the NLRP3 inflammasome MRT-8102 and other NEK7 prog [Read more]